柬埔寨间日疟患者每周伯氨喹抗复发治疗的溶血动态:伴或不伴G6PD缺乏
该研究纳入75例柬埔寨急性间日疟患者,予每周伯氨喹0.75 mg/kg(共8周)及3天双氢青蒿素/哌喹治疗,评估血红蛋白变化。G6PD缺乏、基线血红蛋白较高、基线疟原虫密度较高及地中海贫血影响初始血红蛋白下降;首次伯氨喹暴露后血红蛋白下降最明显,1例G6PD缺乏贫血患者需输血,后续下降无临床意义。
要点
- G6PD缺乏者首次伯氨喹0.75 mg/kg暴露后血红蛋白下降最显著。
- 每周方案后续给药引起的血红蛋白下降无临床意义。
- 治疗第一周需监测血红蛋白,尤其G6PD缺乏者。
核心结论
- 首次伯氨喹0.75 mg/kg暴露与血红蛋白最大下降相关,并导致1例输血,后续给药的血红蛋白下降无临床意义。
- 每周伯氨喹0.75 mg/kg方案在治疗后第一周需要监测,东南亚需要更安全的抗复发方案。
研究设计与样本
- 研究纳入75例柬埔寨急性间日疟患者,年龄5-63岁(中位24岁),男性63例。
- 患者接受每周伯氨喹0.75 mg/kg(共8周)及3天双氢青蒿素/哌喹治疗,测定血红蛋白、网织红细胞计数、G6PD基因型和血红蛋白类型。
主要发现
- 第14天与第7天血红蛋白平均差值0.03 g/dL(范围-0.25-0.32 g/dL);网织红细胞计数第1-3天下降,G6PD正常组第7天达峰,G6PD缺乏组第14天达峰。
- 1例有症状的G6PD缺乏贫血男性患者在第4天接受输血。
临床怎么用
- 对接受每周伯氨喹0.75 mg/kg方案的间日疟患者,应在治疗后第一周监测血红蛋白,尤其G6PD缺乏者。
- G6PD缺乏患者使用该方案时需警惕首次给药后的血红蛋白下降和输血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemoglobin (Hb) data are limited in Southeast Asian glucose-6-phosphate dehydrogenase (G6PD) deficient (G6PD-) patients treated weekly with the World Health Organization-recommended primaquine regimen (ie, 0.75 mg/kg/week for 8 weeks [PQ 0.75]). METHODS: We treated Cambodians who had acute Plasmodium vivax infection with PQ0.75 and a 3-day course of dihydroartemisinin/piperaquine and determined the Hb level, reticulocyte count, G6PD genotype, and Hb type. RESULTS: Seventy-five patients (male sex, 63) aged 5-63 years (median, 24 years) were enrolled. Eighteen were G6PD deficient (including 17 with G6PD Viangchan) and 57 were not G6PD deficient; 26 had HbE (of whom 25 were heterozygous), and 6 had α-/β-thalassemia. Mean Hb concentrations at baseline (ie, day 0) were similar between G6PD deficient and G6PD normal patients (12.9 g/dL [range, 9‒16.3 g/dL] and 13.26 g/dL [range, 9.6‒16 g/dL], respectively; P = .46). G6PD deficiency (P = <.001), higher Hb concentration at baseline (P = <.001), higher parasitemia level at baseline (P = .02), and thalassemia (P = .027) influenced the initial decrease in Hb level, calculated as the nadir level minus the baseline level (range, -5.8-0 g/dL; mean, -1.88 g/dL). By day 14, the mean difference from the day 7 level (calculated as the day 14 level minus the day 7 level) was 0.03 g/dL (range, -0.25‒0.32 g/dL). Reticulocyte counts decreased from days 1 to 3, peaking on day 7 (in the G6PD normal group) and day 14 (in the G6PD deficient group); reticulocytemia at baseline (P = .001), G6PD deficiency (P = <.001), and female sex (P = .034) correlated with higher counts. One symptomatic, G6PD-deficient, anemic male patient was transfused on day 4. CONCLUSIONS: The first PQ0.75 exposure was associated with the greatest decrease in Hb level and 1 blood transfusion, followed by clinically insignificant decreases in Hb levels. PQ0.75 requires monitoring during the week after treatment. Safer antirelapse regimens are needed in Southeast Asia. CLINICAL TRIALS REGISTRATION: ACTRN12613000003774.
引用
- Taylor WRJ, Kheng S, Muth S, et al. Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency. J Infect Dis. 2019. PMID: 31549159. doi:10.1093/infdis/jiz313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。